Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report

Table 3

Baseline characteristics of patients with PD.

Variable	Parkinson’s disease (n = 10), mean	Normal control (n = 39), mean	value
Age	67.80 (7.41)	71.87 (5.50)
Men/women	3/7	13/26
MMSE	28.56 (2.13)	29.90 (0.31)
Plasma lipids
ePE	2.97 (0.76)	4.27 (1.07)	0.001
ePC	4.07 (0.80)	4.33 (0.74)	0.34
SM	29.1 (3.80)	27.99 (3.53)	0.39
Erythrocyte phospholipids
plsPE	7.67 (0.78)	8.56 (0.94)	0.008
PE	9.71 (0.81)	10.12 (1.14)	0.29
PC	23.25 (1.74)	25.02 (2.79)	0.06
SM	49.99 (3.10)	46.99 (4.85)	0.07
PS	9.34 (1.14)	9.31 (1.30)	0.94

Values are mean (SD) unless otherwise specified. ePE: ethanolamine ether phospholipid; ePC: choline ether phospholipid; SM: sphingomyelin; plsPE: ethanolamine plasmalogen; PE: diacyl ethanolamine glycerophospholipid; PC: diacyl choline glycerophospholipid; PS: diacyl serine glycerophospholipid. Based on unpaired t-test for the between-group differences.